Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication.

Rakic B, Sagan SM, Noestheden M, Bélanger S, Nan X, Evans CL, Xie XS, Pezacki JP.

Chem Biol. 2006 Jan;13(1):23-30.

2.

Direct imaging of the disruption of hepatitis C virus replication complexes by inhibitors of lipid metabolism.

Lyn RK, Kennedy DC, Sagan SM, Blais DR, Rouleau Y, Pegoraro AF, Xie XS, Stolow A, Pezacki JP.

Virology. 2009 Nov 10;394(1):130-42. doi: 10.1016/j.virol.2009.08.022. Epub 2009 Sep 10.

3.

The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication.

Sagan SM, Rouleau Y, Leggiadro C, Supekova L, Schultz PG, Su AI, Pezacki JP.

Biochem Cell Biol. 2006 Feb;84(1):67-79.

PMID:
16462891
4.
5.

3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV.

Aly HH, Shimotohno K, Hijikata M.

Biochem Biophys Res Commun. 2009 Feb 6;379(2):330-4. doi: 10.1016/j.bbrc.2008.12.054. Epub 2008 Dec 25.

PMID:
19103167
6.

Targeting lipid metabolism in the treatment of hepatitis C virus infection.

Amemiya F, Maekawa S, Itakura Y, Kanayama A, Matsui A, Takano S, Yamaguchi T, Itakura J, Kitamura T, Inoue T, Sakamoto M, Yamauchi K, Okada S, Yamashita A, Sakamoto N, Itoh M, Enomoto N.

J Infect Dis. 2008 Feb 1;197(3):361-70. doi: 10.1086/525287.

PMID:
18248300
7.

Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha.

Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, van der Laan LJ.

Gastroenterology. 2006 Nov;131(5):1452-62. Epub 2006 Aug 14.

PMID:
17101321
8.

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.

Huang P, Goff DA, Huang Q, Martinez A, Xu X, Crowder S, Issakani SD, Anderson E, Sheng N, Achacoso P, Yen A, Kinsella T, Darwish IS, Kolluri R, Hong H, Qu K, Stauffer E, Goldstein E, Singh R, Payan DG, Lu HH.

Antimicrob Agents Chemother. 2008 Apr;52(4):1419-29. doi: 10.1128/AAC.00525-07. Epub 2008 Jan 28.

9.

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.

Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J.

Hepatology. 2006 Apr;43(4):761-70.

PMID:
16557546
10.

The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus.

Zhang Z, Harris D, Pandey VN.

J Virol. 2008 Jun;82(12):5761-73. doi: 10.1128/JVI.00064-08. Epub 2008 Apr 9.

11.

Zinc is a negative regulator of hepatitis C virus RNA replication.

Yuasa K, Naganuma A, Sato K, Ikeda M, Kato N, Takagi H, Mori M.

Liver Int. 2006 Nov;26(9):1111-8.

PMID:
17032412
12.

Polypyrimidine-tract-binding protein is a component of the HCV RNA replication complex and necessary for RNA synthesis.

Aizaki H, Choi KS, Liu M, Li YJ, Lai MM.

J Biomed Sci. 2006 Jul;13(4):469-80. Epub 2006 May 12.

PMID:
16691359
13.

Microarray analysis identifies a common set of cellular genes modulated by different HCV replicon clones.

Ciccaglione AR, Marcantonio C, Tritarelli E, Tataseo P, Ferraris A, Bruni R, Dallapiccola B, Gerosolimo G, Costantino A, Rapicetta M.

BMC Genomics. 2008 Jun 30;9:309. doi: 10.1186/1471-2164-9-309.

14.

The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T.

J Virol. 2007 Jan;81(2):588-98. Epub 2006 Nov 1.

15.

Inhibition of hepatitis C virus replication and expression by small interfering RNA targeting host cellular genes.

Xue Q, Ding H, Liu M, Zhao P, Gao J, Ren H, Liu Y, Qi ZT.

Arch Virol. 2007;152(5):955-62. Epub 2007 Feb 3.

PMID:
17273891
16.

Impact of steroids on hepatitis C virus replication in vivo and in vitro.

Henry SD, Metselaar HJ, Van Dijck J, Tilanus HW, Van Der Laan LJ.

Ann N Y Acad Sci. 2007 Sep;1110:439-47.

PMID:
17911459
17.

Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication.

Ando M, Korenaga M, Hino K, Ikeda M, Kato N, Nishina S, Hidaka I, Sakaida I.

Liver Int. 2008 Sep;28(8):1158-66. doi: 10.1111/j.1478-3231.2008.01720.x. Epub 2008 Apr 11.

PMID:
18410284
18.

New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.

Mori K, Abe K, Dansako H, Ariumi Y, Ikeda M, Kato N.

Biochem Biophys Res Commun. 2008 Jun 20;371(1):104-9. doi: 10.1016/j.bbrc.2008.04.005. Epub 2008 Apr 10.

PMID:
18406345
19.

Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin.

Paeshuyse J, Coelmont L, Vliegen I, Van hemel J, Vandenkerckhove J, Peys E, Sas B, De Clercq E, Neyts J.

Biochem Biophys Res Commun. 2006 Sep 15;348(1):139-44. Epub 2006 Jul 13.

PMID:
16875675
20.

Potential applications of siRNA in hepatitis C virus therapy.

Smolic R, Volarevic M, Wu CH, Wu GY.

Curr Opin Investig Drugs. 2006 Feb;7(2):142-6. Review.

PMID:
16499284

Supplemental Content

Support Center